Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

The Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate users.

Thurman A, Schwartz JL, Brache V, Chen BA, Chandra N, Kashuba ADM, Weiner DH, Mauck C, Doncel GF.

J Acquir Immune Defic Syndr. 2018 Sep 11. doi: 10.1097/QAI.0000000000001864. [Epub ahead of print]

PMID:
30212395
2.

Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial.

Mitchell JT, LeGrand S, Hightow-Weidman LB, McKellar MS, Kashuba AD, Cottrell M, McLaurin T, Satapathy G, McClernon FJ.

JMIR Mhealth Uhealth. 2018 Sep 10;6(9):e10456. doi: 10.2196/10456.

3.

Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques.

Brocca-Cofano E, Xu C, Wetzel KS, Cottrell ML, Policicchio BB, Raehtz KD, Ma D, Dunsmore T, Haret-Richter GS, Musaitif K, Keele BF, Kashuba AD, Collman RG, Pandrea I, Apetrei C.

J Virol. 2018 Aug 16;92(17). pii: e00576-18. doi: 10.1128/JVI.00576-18. Print 2018 Sep 1.

PMID:
29925666
4.

Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.

Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD, Dellon ES, De Paris K, Nelson JA, Gay CL, Kashuba AD.

Antivir Ther. 2018 May 1. doi: 10.3851/IMP3236. [Epub ahead of print]

PMID:
29714167
5.

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.

McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivro A, Nagelkerke N, Garcia Lerma JG, Kashuba AD, Masson L, Mansoor LE, Karim QA, Karim SSA, Passmore JS.

Nat Med. 2018 May;24(4):491-496. doi: 10.1038/nm.4506. Epub 2018 Feb 26.

6.

Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Srinivas N, Maffuid K, Kashuba ADM.

Clin Pharmacokinet. 2018 Sep;57(9):1059-1074. doi: 10.1007/s40262-018-0632-y. Review.

PMID:
29464550
7.

Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.

Shen Z, Rodriguez-Garcia M, Patel MV, Bodwell J, Kashuba ADM, Wira CR.

Sci Rep. 2017 Dec 18;7(1):17697. doi: 10.1038/s41598-017-18078-3.

8.

The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue.

Nicol MR, Brewers LM, Kashuba ADM, Sykes C.

AIDS. 2018 Jan 2;32(1):11-15. doi: 10.1097/QAD.0000000000001678.

PMID:
29112071
9.

Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.

Schauer AP, Sykes C, Cottrell ML, Prince H, Kashuba ADM.

J Pharm Biomed Anal. 2018 Feb 5;149:40-45. doi: 10.1016/j.jpba.2017.10.030. Epub 2017 Oct 31.

PMID:
29100029
10.

Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.

Asmuth DM, Thompson CG, Chun TW, Ma ZM, Mann S, Sainz T, Serrano-Villar S, Utay NS, Garcia JC, Troia-Cancio P, Pollard RB, Miller CJ, Landay A, Kashuba AD.

J Infect Dis. 2017 Oct 17;216(7):813-818. doi: 10.1093/infdis/jix418.

PMID:
28968888
11.

Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.

Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, Kashuba ADM, Lee CR, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell JR.

Clin Transl Sci. 2017 Nov;10(6):443-454. doi: 10.1111/cts.12490. Epub 2017 Aug 10. Review. No abstract available.

12.

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD, Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM.

J Clin Invest. 2017 Aug 1;127(8):3126-3135. doi: 10.1172/JCI92684. Epub 2017 Jul 17.

13.

Multimodal analysis of drug transporter expression in gastrointestinal tissue.

Thompson CG, Fallon JK, Mathews M, Charlins P, Remling-Mulder L, Kovarova M, Adamson L, Srinivas N, Schauer A, Sykes C, Luciw P, Garcia JV, Akkina R, Smith PC, Kashuba ADM.

AIDS. 2017 Jul 31;31(12):1669-1678. doi: 10.1097/QAD.0000000000001554.

14.

A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.

Feder AF, Kline C, Polacino P, Cottrell M, Kashuba ADM, Keele BF, Hu SL, Petrov DA, Pennings PS, Ambrose Z.

PLoS Pathog. 2017 May 25;13(5):e1006358. doi: 10.1371/journal.ppat.1006358. eCollection 2017 May.

15.

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

PLoS Pathog. 2017 May 3;13(5):e1006368. doi: 10.1371/journal.ppat.1006368. eCollection 2017 May.

16.

HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities.

Thompson CG, Gay CL, Kashuba ADM.

AIDS Res Hum Retroviruses. 2017 Jun;33(6):513-523. doi: 10.1089/AID.2016.0253. Epub 2017 May 16. Review.

17.

Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.

Cottrell ML, Garrett KL, Prince HMA, Sykes C, Schauer A, Emerson CW, Peery A, Rooney JF, McCallister S, Gay C, Kashuba ADM.

J Antimicrob Chemother. 2017 Jun 1;72(6):1731-1740. doi: 10.1093/jac/dkx064.

18.

Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.

Wahl A, Ho PT, Denton PW, Garrett KL, Hudgens MG, Swartz G, O'Neill C, Veronese F, Kashuba AD, Garcia JV.

Sci Rep. 2017 Feb 1;7:41098. doi: 10.1038/srep41098.

19.

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.

Imaz A, Martinez-Picado J, Niubó J, Kashuba AD, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczer D.

J Infect Dis. 2016 Nov 15;214(10):1512-1519. Epub 2016 Aug 30.

20.

Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers.

Asher GN, Xie Y, Moaddel R, Sanghvi M, Dossou KS, Kashuba AD, Sandler RS, Hawke RL.

J Clin Pharmacol. 2017 Feb;57(2):185-193. doi: 10.1002/jcph.806. Epub 2016 Sep 6.

21.

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.

Khandelwal P, Fukuda T, Mizuno K, Teusink-Cross A, Mehta PA, Marsh RA, Kashuba ADM, Vinks AA, Davies SM.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1829-1835. doi: 10.1016/j.bbmt.2016.08.001. Epub 2016 Aug 3.

22.

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

Imaz A, Niubó J, Kashuba AD, Ferrer E, Sykes C, Rozas N, Acerete L, Vila A, Podzamczer D.

HIV Med. 2017 Mar;18(3):225-230. doi: 10.1111/hiv.12417. Epub 2016 Aug 1.

PMID:
27477062
23.

Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.

Slaven JE, Decker BS, Kashuba ADM, Atta MG, Wyatt CM, Gupta SK.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):e8-e10. doi: 10.1097/QAI.0000000000001106. No abstract available.

24.

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

PLoS Pathog. 2016 Mar 25;12(3):e1005540. doi: 10.1371/journal.ppat.1005540. eCollection 2016 Mar. No abstract available.

25.

Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB, Kashuba AD.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):498-506. doi: 10.1097/QAI.0000000000000996.

26.

Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.

Oramasionwu CU, Kashuba AD, Napravnik S, Wohl DA, Mao L, Adimora AA.

World J Hepatol. 2016 Mar 8;8(7):368-75. doi: 10.4254/wjh.v8.i7.368.

27.

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, Nelson JA, Kashuba AD.

J Infect Dis. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077. Epub 2016 Feb 24.

28.

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.

Chang AT, Bertino JS Jr, Nafziger AN, Kashuba AD, Turpault S, Lewis LD, Ma JD.

Ther Drug Monit. 2016 Jun;38(3):383-7. doi: 10.1097/FTD.0000000000000277.

PMID:
26818625
29.

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

PLoS Pathog. 2016 Jan 21;12(1):e1005381. doi: 10.1371/journal.ppat.1005381. eCollection 2016 Jan. Erratum in: PLoS Pathog. 2016 Mar;12(3):e1005540. Wook-Chun, Tae [corrected to Chun, Tae-Wook]. PLoS Pathog. 2017 May 3;13(5):e1006368.

30.

Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.

Veselinovic M, Yang KH, Sykes C, Remling-Mulder L, Kashuba AD, Akkina R.

Virology. 2016 Feb;489:173-8. doi: 10.1016/j.virol.2015.12.014. Epub 2016 Jan 6.

31.

Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging.

Rosen EP, Thompson CG, Bokhart MT, Prince HM, Sykes C, Muddiman DC, Kashuba AD.

Anal Chem. 2016 Jan 19;88(2):1336-44. doi: 10.1021/acs.analchem.5b03794. Epub 2015 Dec 30.

32.

Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.

Melody K, McBeth S, Kline C, Kashuba AD, Mellors JW, Ambrose Z.

Antimicrob Agents Chemother. 2015 Dec;59(12):7762-70. doi: 10.1128/AAC.01937-15. Epub 2015 Oct 5.

33.

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):32-43. doi: 10.1089/AID.2015.0182. Epub 2015 Oct 15.

34.

Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.

Floris-Moore MA, Mollan K, Wilkin AM, Johnson MA, Kashuba AD, Wohl DA, Patterson KB, Francis O, Kronk C, Eron JJ.

Antivir Ther. 2016;21(1):55-64. doi: 10.3851/IMP2982. Epub 2015 Aug 11.

35.

Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.

Dumond JB, Yang KH, Kendrick R, Reddy YS, Kashuba AD, Troiani L, Bridges AS, Fiscus SA, Forrest A, Cohen MS.

Antimicrob Agents Chemother. 2015 Oct;59(10):6395-401. doi: 10.1128/AAC.01148-15. Epub 2015 Aug 3.

36.

Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.

Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):510-4. doi: 10.1097/QAI.0000000000000777.

37.

Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.

Kashuba AD, Gengiah TN, Werner L, Yang KH, White NR, Karim QA, Abdool Karim SS.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):264-9. doi: 10.1097/QAI.0000000000000607.

38.

Co-localized confocal Raman spectroscopy and optical coherence tomography (CRS-OCT) for depth-resolved analyte detection in tissue.

Maher JR, Chuchuen O, Henderson MH, Kim S, Rinehart MT, Kashuba AD, Wax A, Katz DF.

Biomed Opt Express. 2015 May 8;6(6):2022-35. doi: 10.1364/BOE.6.002022. eCollection 2015 Jun 1.

39.

Bottlenecks in HIV-1 transmission: insights from the study of founder viruses.

Joseph SB, Swanstrom R, Kashuba AD, Cohen MS.

Nat Rev Microbiol. 2015 Jul;13(7):414-25. doi: 10.1038/nrmicro3471. Epub 2015 Jun 8. Review.

40.

Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.

Cottrell ML, Patterson KB, Prince HM, Jones A, White N, Wang R, Kashuba AD.

Antivir Ther. 2015;20(8):795-803. doi: 10.3851/IMP2968. Epub 2015 Jun 3.

41.

Pharmacokinetics of antiretrovirals in mucosal tissue.

Cottrell ML, Srinivas N, Kashuba AD.

Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):893-905. doi: 10.1517/17425255.2015.1027682. Epub 2015 Mar 22. Review.

42.

Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs.

Thompson CG, Bokhart MT, Sykes C, Adamson L, Fedoriw Y, Luciw PA, Muddiman DC, Kashuba AD, Rosen EP.

Antimicrob Agents Chemother. 2015 May;59(5):2944-8. doi: 10.1128/AAC.04952-14. Epub 2015 Mar 2.

43.

Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.

Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV.

AIDS. 2015 Jan 28;29(3):331-7.

PMID:
25503265
44.

Models for predicting effective HIV chemoprevention in women.

Nicol MR, Emerson CW, Prince HM, Nelson JA, Fedoriw Y, Sykes C, Geller EJ, Patterson KB, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):369-76. doi: 10.1097/QAI.0000000000000472.

45.

Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.

Rahangdale L, De Paris K, Kashuba AD, Nelson JA, Cottrell M, Sykes C, Emerson C, Young SL, Stevens T, Patterson KB, Cohen MS.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):420-4. doi: 10.1097/QAI.0000000000000480.

46.

Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.

Jacot TA, Nelson A, Thurman A, Kashuba AD, Archer DF, Doncel GF.

PLoS One. 2014 Dec 9;9(12):e114368. doi: 10.1371/journal.pone.0114368. eCollection 2014.

47.

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.

Sabo JP, Kort J, Ballow C, Kashuba AD, Haschke M, Battegay M, Girlich B, Ting N, Lang B, Zhang W, Cooper C, O'Brien D, Seibert E, Chan TS, Tweedie D, Li Y.

J Clin Pharmacol. 2015 Apr;55(4):467-77. doi: 10.1002/jcph.436. Epub 2015 Jan 14.

PMID:
25449227
48.

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.

Yang KH, Hendrix C, Bumpus N, Elliott J, Tanner K, Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA, Kashuba AD.

PLoS One. 2014 Oct 28;9(10):e106196. doi: 10.1371/journal.pone.0106196. eCollection 2014.

49.

Quantitative mass spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix-assisted laser desorption electrospray ionization.

Bokhart MT, Rosen E, Thompson C, Sykes C, Kashuba AD, Muddiman DC.

Anal Bioanal Chem. 2015 Mar;407(8):2073-84. doi: 10.1007/s00216-014-8220-y. Epub 2014 Oct 16.

50.

HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.

Veselinovic M, Yang KH, LeCureux J, Sykes C, Remling-Mulder L, Kashuba ADM, Akkina R.

Virology. 2014 Sep;464-465:253-263. doi: 10.1016/j.virol.2014.07.008. Epub 2014 Aug 7.

Supplemental Content

Loading ...
Support Center